 has announced the graduation of 10 technology companies from the third cohort of the Scale Now programme.</p><p> </p><p>Simultaneously, the MCIT launched the programme’s fourth cohort with the participation of 12 new companies, reaffirming its commitment to accelerating the growth of promising technology ventures and further strengthening Qatar’s position as a regional hub for innovation and digital entrepreneurship.</p><p> </p><p>The graduating companies have developed innovative solutions across a range of strategic sectors, including industrial technologies, health technologies, media technologies, agricultural technologies, e-commerce, enterprise technologies, and logistics.</p><p> </p><p>The diversity reflects the strength of Qatar’s technology entrepreneurship ecosystem and the programme’s role in supporting companies that develop innovative solutions to address the evolving needs of local and international markets.</p><p> </p><p>The graduating cohort in the Industrial Technologies sector includes Syook, which operates as a no-code Industrial IoT and AI platform enabling real-time asset tracking, safety, and compliance. Alongside it, Digital Petroleum provides patented AI sensor technology designed to enable instant digitalisation of industrial plants.</p><p> </p><p>Within HealthTech, Medica serves as a healthcare fintech platform automating insurance and revenue cycle management for hospitals and clinics, while Eshfaa functions as a digital healthcare and medical tourism platform coordinating care for local and international patients.</p><p> </p><p>In MediaTech & Publishing, Aligator offers an AI media intelligence platform that monitors and improves organisational reputation in Arabic and English.</p><p> </p><p>Complementing this, Rawi is an Arabic audio platform producing audiobooks, educational programmes, documentaries, edutainment, and podcasts.</p><p> </p><p>In Agritech, Growa delivers data-driven farming solutions through IoT, AI, GNSS, and agronomic expertise. Meanwhile, in e-commerce, Genio provides a cashless payment and nutrition-tracking system enabling parents to monitor their children’s spending and food consumption at school.</p><p> </p><p>For Enterprise Tech, Byanat acts as an AI observability platform analysing telecom and data centre infrastructure performance and recommending optimisations.</p><p> </p><p>In Logistics, WareOne operates as an asset-light logistics orchestrator delivering on-demand, tailored supply chain solutions across the value chain.</p><p> </p><p>Across its first three cohorts, the Scale Now programme has delivered tangible results that reflect its impact in supporting the growth of high-potential technology companies. Participating companies have collectively secured investments secured approximately $13.8mn in funding, closed 388 B2B deals, and achieved an average 32% revenue growth.</p><p> </p><p>In addition, entrepreneurs participating in the programme have benefited from 569 hours of dedicated advisory support, while the programme achieved an overall participant satisfaction rate of 89%, underscoring the quality of the experience and value delivered to participating companies.</p><p> </p><p>Faraj Abdulla, director of Digital Economy Department at MCIT, said: “The graduation of the third cohort of the Scale Now programme reflects the tangible outcomes the programme has achieved in supporting high-potential technology companies and enabling them to grow, expand, and access new markets.”</p><p> </p><p>Ali al-Mawlawi, director of Business Development Department at MCIT, said: “This initiative reflects our commitment to empowering startups, fostering innovation, and advancing the Digital Agenda 2030, further reinforcing Qatar’s position as a leading hub for the digital economy.”</p><p> </p><p>The third cohort concluded with WareOne successfully expanding its operations into Saudi Arabia. Sheikh Khalifa al-Thani, founder and CEO of WareOne, said: “When we joined the Scale Now programme, our goal was to better understand the local market. However, the programme delivered far more than we expected.”</p><p> </p><p>Alongside the graduation of the third cohort, the MCIT also announced the launch of the fourth cohort of the Scale Now programme, welcoming 12 new technology companies.</p><p> </p>__%20%20%20%20<p>Related%20Story</p>_%20%20%20%20_%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20_%20%20%20%20%20%20%20%20%20%20%20_%20%20%20%20%20%20%20%20%20%20%20%20_%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20_%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20__%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20<img%20loading=?resize=150,150&ssl=1 "MCIT celebrates graduation of 10 firms of Scale Now programme")
Weight-loss jabs are the most recent craze for losing a couple of kilos. Their impact has been dramatic with medication equivalent to Ozempic and Wegovy (semaglutide) inflicting customers to lose as much as 15% in their frame fats on moderate.
Semaglutide, which is a glucagon-like peptide 1 (GLP-1 receptor agonist drug), mimics the motion of a herbal intestine hormone which is launched once we consume.
This intestine hormone triggers more than one physiological responses that play a task in regulating frame weight, equivalent to liberating insulin to assist keep watch over blood sugar ranges, slowing abdomen emptying (so we really feel fuller for longer) or even telling the mind’s starvation centres to suppress urge for food.
However as efficient as GLP-1 medication are, now not everybody who makes use of them will lose an important quantity of weight. So-called “non-responders” are individuals who lose lower than 5% in their frame weight after kind of six months of remedy at the absolute best tolerated dose. Analysis means that between 10% and 30% of sufferers have compatibility into this staff.
Many of us labelled as non-responders to GLP-1 receptor agonists equivalent to semaglutide don’t take the medicine as it should be or discontinue remedy ahead of good enough healing impact may also be completed. Research display as much as 20-60% of other folks other folks forestall remedy throughout the first 12 months, and standard use of the drug in doses beneath the advisable quantities.
Sure metabolic problems equivalent to insulin resistance, the place the frame’s cells forestall responding correctly to insulin, may additionally block semaglutide’s movements. Sleep disruption may just inhibit the drug’s movements as smartly, as deficient sleep is proven to extend the discharge of the frame’s herbal GLP-1 hormone.
Related News
Folks taking different drugs, equivalent to corticosteroids and psychotropic medication (equivalent to antidepressants) which will motive weight achieve, may additionally to find GLP-1 medication don’t paintings rather well for them.
However those aren’t the one causes an individual could also be labelled a non-responder.
Apparently, intercourse would possibly play a task in how an individual responds to those medication, with analysis appearing ladies taking semaglutide constantly lose extra weight in comparison to males.
A evaluate of 47 randomised managed trials involving over 23,000 sufferers discovered that the best weight-loss impact from GLP-1 medication was once proven in members who have been younger, feminine and now not identified with diabetes (so that they due to this fact had higher insulin sensitivity).
Related News
One reason ladies react higher might be their upper oestrogen ranges. This hormone improves insulin sensitivity and stimulates GLP-1 secretion.
Weight-loss jabs seem to paintings higher for ladies.
MillaF/ Shutterstock
One more reason some other folks reply poorly to GLP-1 medication is on account of their genetic make-up.
Scientists have known variants within the gene coding for the enzyme PAM (peptidyl-glycine alpha-amidating monooxygenase) that looks to motive GLP-1 resistance. This genetic exchange is carried by means of roughly 10% of the inhabitants.
Folks with this genetic exchange have upper circulating ranges of GLP-1 however with out the anticipated organic impact. Which means extra GLP-1 hormone is wanted to succeed in the similar reaction in other folks with out the mutation. This implies a transparent resistance to the hormone.
Analysis which seemed on the genetics of just about 28,000 other folks taking a GLP-1 drug additionally known genetic problems in any other set of receptor genes known as GLP-1R and GIPR.
This genetic factor led to variations in each weight reduction and uncomfortable side effects. Those that had those genetic problems had upper frame mass index (BMI) and frame mass on moderate, and have been much more likely to have kind 1 diabetes and different metabolic problems. Such genetic variations would possibly provide an explanation for why some other folks fail to lose any weight when taking a GLP-1 drug.
Every other issue that can give a contribution for non-responders pertains to the reasons of weight problems itself. Our frame operates in line with 4 distinct forms of starvation. If a medicine goals one thing that isn’t the number one reason for an individual’s weight problems, the reaction noticed can be small.
The primary kind is our baseline slow-burn starvation, which is the minimal choice of energy our frame completely will have to eat as a way to serve as (sometimes called our metabolic fee). Every other form of starvation is hungry intestine, pertains to a real, physiological want to consume. The way in which we consume may also be pushed by means of our mind (referred to as a hungry mind, the place we consume from dependancy or rigidity) or our feelings (referred to as emotional starvation, the place we consume to deal with how we really feel).
For sufferers with emotional starvation, GLP-1 medication don’t cope with the basis reason for the nervousness and despair using that particular person’s overeating. In line with one observational find out about performed in Japan, emotional eaters have been much less more likely to see important weight adjustments when the use of a GLP-1 drug remedy.
Integrating cognitive behavioural treatment would possibly due to this fact be essential for individuals who combat with emotional starvation and are the use of as GLP-1 drug. For hungry intestine sufferers, a high-protein, high-fibre nutrition can give a boost to the drug’s effectiveness.
For sufferers with a hungry mind, switching to twin agonists equivalent to tirzepatide (commercially referred to as Mounjaro), which goals two digestive hormones, GLP-1 and glucose-dependent insulinotropic peptide (GIP) could also be helpful. For slow-burn starvation, resistance coaching can building up resting metabolic fee.
Whilst weight-loss medication have confirmed efficient for lots of, the truth that they don’t paintings for everybody displays how essential it’s to transport in opposition to creating precision weight problems drugs. This may contain analysing a affected person’s distinctive genes and way of life patterns to compare them with the proper medicine. Whilst genetic checking out for variants connected to non reaction isn’t not unusual, it represents the next move in serving to be certain sufferers are given treatments that paintings higher for them.
